Palisade Bio and Newsoara Announce Completion of Phase 2 Study in GI Surgery Study in China
07 mai 2021 09h07 HE
|
Palisade Bio, Inc.
CARLSBAD, Calif. and SHANGHAI, China, May 07, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), and co-development partner Newsoara today announce completion of a Phase 2 clinical trial...
Palisade Bio Hosting Key Opinion Leader Webinar on LB1148, an Oral Serine Protease Inhibitor for Postoperative GI Dysfunction
04 mai 2021 08h00 HE
|
Palisade Bio, Inc.
CARLSBAD, Calif., May 04, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications,...
Leading BioSciences Closes Merger with Seneca Biopharma and Set to Begin Trading on Nasdaq as PALI
27 avr. 2021 16h02 HE
|
Palisade Bio, Inc.
The combined company, Palisade Bio, Inc., is expected to commence trading on the Nasdaq Capital Market under the ticker symbol “PALI” on April 28, 2021 Concurrent $20.0 million private placement...
Leading BioSciences Announces Early Efficacy Signal in Reducing Post-Surgical Adhesions in Open Label Study
20 avr. 2021 07h00 HE
|
Leading BioSciences
CARLSBAD, Calif., April 20, 2021 (GLOBE NEWSWIRE) -- Leading BioSciences, Inc. (“LBS” or "the Company"), a privately held company that recently entered into a definitive agreement for a reverse...
Leading BioSciences Provides Update to Seneca Biopharma, Inc. Stockholders on Merger Closing Process Following Virtual Special Meeting on April 23, 2021 and Upcoming Milestones Following Planned Close of Merger
19 avr. 2021 07h00 HE
|
Leading BioSciences
Video message details merger closing process following completion of the April 23 virtual Special Meeting as well as next planned milestones for the merged company to be renamed Palisade Bio As of...
Leading BioSciences Releases Video Message Encouraging Seneca Biopharma, Inc. Stockholders to Vote at the Virtual Special Meeting on April 23, 2021
12 avr. 2021 23h15 HE
|
Leading BioSciences
Video messages urges Seneca stockholders to vote in support of Proposal #1, the reverse stock split, in order to approve the proposed transaction. Proposal 1 was favored by a wide margin by Seneca...
Leading BioSciences Releases Video Message Highlighting Compelling Investment Thesis of Proposed Merger with Seneca Biopharma, Inc.
02 avr. 2021 11h35 HE
|
Leading BioSciences
Video message explains the multiple benefits of the proposed merger and provides an overview of the substantial market opportunity for the combined company to be named Palisade Bio Seneca...
Leading BioSciences Encourages Seneca Biopharma Stockholders to Vote “FOR” Proposed Merger
31 mars 2021 16h05 HE
|
Leading BioSciences
Combined company, to be named Palisade Bio, will be well-positioned to leverage its compelling therapeutics pipeline, strong cash position, and accomplished management and Board to maximize...
Leading BioSciences to Present at the H.C. Wainwright Global Life Sciences Conference
02 mars 2021 08h30 HE
|
Leading BioSciences
CARLSBAD, Calif., March 02, 2021 (GLOBE NEWSWIRE) -- Leading BioSciences, Inc. (“LBS”), a privately held company that recently entered into a definitive agreement for a reverse merger with Seneca...
Leading BioSciences Announces FDA Fast Track Designation Granted to LB1148 for the Treatment of Postoperative Gastrointestinal Dysfunction Associated with Pediatric Cardiovascular Surgery
13 janv. 2021 08h30 HE
|
Leading BioSciences
CARLSBAD, Calif., Jan. 13, 2021 (GLOBE NEWSWIRE) -- Leading BioSciences, Inc. (“LBS”), a privately held company that recently entered into a definitive agreement for a reverse merger with Seneca...